Combination therapy with androgen receptor N‐terminal domain antagonist EPI‐7170 and enzalutamide yields synergistic activity in AR‐V7‐positive prostate cancer

Resistance of castration‐resistant prostate cancer (CRPC) to enzalutamide and abiraterone involves the expression of constitutively active, truncated androgen receptor (AR) splice variants (AR‐Vs) that lack a C‐terminal ligand‐binding domain (LBD). Both full‐length AR and truncated AR‐Vs require a f...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Mol Oncol
Hlavní autoři: Hirayama, Yukiyoshi, Tam, Teresa, Jian, Kunzhong, Andersen, Raymond J., Sadar, Marianne D.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2020
Témata:
Research Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7530779/
https://ncbi.nlm.nih.gov/pubmed/32734688
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12770
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky